Q4 2025 · 13F-HR
Krensavage Asset Management, LLCholdings as filed
Filed 2026-02-18 · accession 0001609251-26-000003
$283,112
Reported value
18
Positions
2025-12-31
Period end
The Brief · Krensavage Asset Management, LLC · Q4 2025
AI · grounded in 13F
Krensavage Asset Management, LLC reduced its position in GSK by 64.4%. The fund also trimmed its holdings in ALKS by 48.1% and SUPN by 13.8%. On the buy side, the manager accumulated shares of ENTA by 30.8% and BMRN by 29.4%, while establishing a new position in RARE valued at $3,442.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 91307C102 | UTHR | UNITED THERAPEUTICS CORP | $44,477 | 15.7% | 91,282 | Common | SOLE |
| 29251M106 | ENTA | ENANTA PHARMACEUTICALS INC | $43,626 | 15.4% | 2,766,390 | Common | SOLE |
| 09061G101 | BMRN | BIOMARIN PHARMACEUTICAL INC | $31,188 | 11.0% | 524,786 | Common | SOLE |
| G50871105 | JAZZ | JAZZ PHARMACEUTICALS PLC | $28,529 | 10.1% | 167,816 | Common | SOLE |
| 30161Q104 | EXEL | EXELIXIS INC | $21,631 | 7.64% | 493,526 | Common | SOLE |
| G29687103 | AVDL | AVADEL PHARMACEUTICALS | $18,444 | 6.51% | 855,860 | Common | SOLE |
| 80105N105 | SNY | SANOFI-ADR | $15,698 | 5.54% | 323,946 | Common | SOLE |
| 868459108 | SUPN | SUPERNUS PHARMACEUTICALS INC | $15,581 | 5.50% | 313,499 | Common | SOLE |
| 14149Y108 | CAH | CARDINAL HEALTH INC | $15,155 | 5.35% | 73,745 | Common | SOLE |
| G4766E116 | INDV | INDIVIOR PLC | $12,182 | 4.30% | 339,532 | Common | SOLE |
| 921659108 | VNDA | VANDA PHARMACEUTICALS INC | $10,411 | 3.68% | 1,180,388 | Common | SOLE |
| 09075V102 | BNTX | BIONTECH SE-ADR | $9,475 | 3.35% | 99,523 | Common | SOLE |
| 37733W204 | GSK | GSK PLC-SPON ADR | $4,744 | 1.68% | 96,729 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $3,442 | 1.22% | 149,634 | Common | SOLE |
| 75886F107 | REGN | REGENERON PHARMACEUTICALS | $3,087 | 1.09% | 4,000 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $3,017 | 1.07% | 107,822 | Common | SOLE |
| 09062X103 | BIIB | BIOGEN INC | $1,760 | 0.62% | 10,000 | Common | SOLE |
| 30052C107 | EOLS | EVOLUS INC | $665 | 0.23% | 100,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.